Advancing precision care
Many existing therapies for cancer and rare diseases are non-selective, impacting healthy tissue and vital organs while treating the disease. Our radiopharmaceuticals are designed to deliver focused doses of radiation with precision targeting via an injection, regardless of where the cancer or disease is in the body.
We use a radioactive isotope as a payload, attached to a targeting agent – such as a small molecule or antibody – with an affinity for targeted biomarkers on the surface of cancerous or diseased cells. Depending on the choice of radioisotope payload, either imaging or therapy can be delivered. This specificity of the targeting agent is designed to concentrate radiation at the tumour sites and to limit off-target tissue exposure.
Telix business units
Telix’s business model reflects our focus as a therapeutics-led radiopharmaceutical company committed to precision oncology.
The therapeutics unit sits at the core of Telix, leading the Company’s therapeutic pipeline commercialisation and business development.
Telix is focused on developing therapies for urologic (prostate and kidney), neurologic (brain) and musculoskeletal (sarcoma) cancers.
Therapeutics (Tx)
The therapeutics unit sits at the core of Telix, leading the Company’s therapeutic pipeline commercialisation and business development.
Telix is focused on developing therapies for urologic (prostate and kidney), neurologic (brain) and musculoskeletal (sarcoma) cancers.
The Precision Medicine unit support the Therapeutics unit by enabling the delivery of personalised theranostic solutions to market using Telix’s diagnostics.
Diagnostics such as Telix’s approved PSMA-PET/CT imaging agent, Illuccix®, are key to informing treatment decisions and critical to developing and delivering effective therapeutic solutions.
Precision Medicine (Px)
The Precision Medicine unit support the Therapeutics unit by enabling the delivery of personalised theranostic solutions to market using Telix’s diagnostics.
Diagnostics such as Telix’s approved PSMA-PET/CT imaging agent, Illuccix®, are key to informing treatment decisions and critical to developing and delivering effective therapeutic solutions.
Lightpoint provides surgical solutions and digital products that power Telix’s cancer treatment portfolio.
This includes the SENSEI® miniature gamma probe for minimally invasive and robotic-assisted surgery, dosimetry software for personalised treatment plans, and artificial intelligence platforms aimed at achieving faster and more accurate diagnoses.
Lightpoint (Medtech)
Lightpoint provides surgical solutions and digital products that power Telix’s cancer treatment portfolio.
This includes the SENSEI® miniature gamma probe for minimally invasive and robotic-assisted surgery, dosimetry software for personalised treatment plans, and artificial intelligence platforms aimed at achieving faster and more accurate diagnoses.
Telix Manufacturing Solutions is a global network of facilities designed to deliver patient doses worldwide.
We are building manufacturing capacity and developing new technologies and processes to allow us to deliver products at scale in a rapidly growing radiopharmaceutical sector.
Telix Manufacturing Solutions
Telix Manufacturing Solutions is a global network of facilities designed to deliver patient doses worldwide.
We are building manufacturing capacity and developing new technologies and processes to allow us to deliver products at scale in a rapidly growing radiopharmaceutical sector.
Telix Group Companies
Telix is headquartered in Melbourne, Australia with operations in the United States, Europe (Belgium and Switzerland) and Japan.
In 2023 we opened our state-of-the-art radiopharmaceutical production facility in Belgium – one of the largest of its kind in Europe. Telix Manufacturing Solutions will deliver significant operational flexibility, research and development capabilities, and support commercial production requirements in Europe and worldwide.
Disease areas and programs
Telix’s research pipeline aims to address significant unmet medical need in urologic oncology (prostate and kidney), neuro-oncology (glioma), musculoskeletal oncology (sarcoma) and bone marrow conditioning.
